Shares of United Therapeutics (UTHR) are down $41.40, or 13%, to $287.00 in pre-market trading after Insmed (INSM) announced positive topline results from its randomized, double-blind, placebo-controlled Phase 2b study evaluating the efficacy and safety of treprostinil palmitil inhalation powder, or TPIP, administered once daily in patients with pulmonary arterial hypertension.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- Liquidia price target raised to $32 from $25 at Needham
- Liquidia schedules first commercial shipment of YUTREPIA
- United Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Maintaining Market Position: United Therapeutics’ Tyvaso DPI Amidst Competition and Future Growth Prospects
- Liquidia price target raised to $23 from $20 at Wells Fargo
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue